Literature DB >> 23720715

Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33.

Lauren E Mays1, Lili Wang, Rebeca Tenney, Peter Bell, Hyun-Joo Nam, Jianping Lin, Brittney Gurda, Kim Van Vliet, Kyle Mikals, Mavis Agbandje-McKenna, James M Wilson.   

Abstract

Avoiding activation of immunity to vector-encoded proteins is critical to the safe and effective use of adeno-associated viral (AAV) vectors for gene therapy. While commonly used serotypes, such as AAV serotypes 1, 2, 7, 8, and 9, are often associated with minimal and/or dysfunctional CD8(+) T cell responses in mice, the threshold for immune activation appears to be lower in higher-order species. We have modeled this discrepancy within the mouse by identifying two capsid variants with differential immune activation profiles: AAV serotype 8 (AAV8) and a hybrid between natural rhesus isolates AAVrh32 and AAVrh33 (AAVrh32.33). Here, we aimed to characterize the structural determinants of the AAVrh32.33 capsid that augment cellular immunity to vector-encoded proteins or those of AAV8 that may induce tolerance. We hypothesized that the structural domain responsible for differential immune activation could be mapped to surface-exposed regions of the capsid, such as hypervariable regions (HVRs) I to IX of VP3. To test this, a series of hybrid AAV capsids was constructed by swapping domains between AAV8 and AAVrh32.33. By comparing their ability to generate transgene-specific T cells in vivo versus the stability of transgene expression in the muscle, we confirmed that the functional domain lies within the VP3 portion of the capsid. Our studies were able to exclude the regions of VP3 which are not sufficient for augmenting the cellular immune response, notably, HVRs I, II, and V. We have also identified HVR IV as a region of interest in conferring the efficiency and stability of muscle transduction to AAVrh32.33.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23720715      PMCID: PMC3754105          DOI: 10.1128/JVI.00596-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

2.  Structurally mapping the diverse phenotype of adeno-associated virus serotype 4.

Authors:  Lakshmanan Govindasamy; Eric Padron; Robert McKenna; Nicholas Muzyczka; Nikola Kaludov; John A Chiorini; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Structure of adeno-associated virus serotype 8, a gene therapy vector.

Authors:  Hyun-Joo Nam; Michael Douglas Lane; Eric Padron; Brittney Gurda; Robert McKenna; Erik Kohlbrenner; George Aslanidi; Barry Byrne; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

4.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

5.  Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.

Authors:  Seiichiro Mori; Lina Wang; Takamasa Takeuchi; Tadahito Kanda
Journal:  Virology       Date:  2004-12-20       Impact factor: 3.616

6.  Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3.

Authors:  S Muramatsu; H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-07-01       Impact factor: 3.616

7.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Cloning and characterization of adeno-associated virus type 5.

Authors:  J A Chiorini; F Kim; L Yang; R M Kotin
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells.

Authors:  Lauren E Mays; Lili Wang; Jianping Lin; Peter Bell; Alison Crawford; E John Wherry; James M Wilson
Journal:  Mol Ther       Date:  2013-06-19       Impact factor: 11.454

10.  Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins.

Authors:  Lauren E Mays; Luk H Vandenberghe; Ru Xiao; Peter Bell; Hyun-Joo Nam; Mavis Agbandje-McKenna; James M Wilson
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more
  11 in total

Review 1.  Strategies to circumvent humoral immunity to adeno-associated viral vectors.

Authors:  Longping V Tse; Sven Moller-Tank; Aravind Asokan
Journal:  Expert Opin Biol Ther       Date:  2015-06       Impact factor: 4.388

2.  In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector.

Authors:  Eric Zinn; Simon Pacouret; Vadim Khaychuk; Heikki T Turunen; Livia S Carvalho; Eva Andres-Mateos; Samiksha Shah; Rajani Shelke; Anna C Maurer; Eva Plovie; Ru Xiao; Luk H Vandenberghe
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

3.  GPR108 Is a Highly Conserved AAV Entry Factor.

Authors:  Amanda M Dudek; Nerea Zabaleta; Eric Zinn; Sirika Pillay; James Zengel; Caryn Porter; Jennifer Santos Franceschini; Reynette Estelien; Jan E Carette; Guo Ling Zhou; Luk H Vandenberghe
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

Review 4.  Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Authors:  Natalie F Nidetz; Michael C McGee; Longping V Tse; Chengwen Li; Le Cong; Yunxing Li; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

5.  The structure of AAVrh32.33, a novel gene delivery vector.

Authors:  Kyle Mikals; Hyun-Joo Nam; Kim Van Vliet; Luk H Vandenberghe; Lauren E Mays; Robert McKenna; James M Wilson; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2014-04-02       Impact factor: 2.867

6.  Viral Vector Technologies and Strategies: Improving on Nature.

Authors:  Roxanne H Croze; Melissa Kotterman; Christian H Burns; Chris E Schmitt; Melissa Quezada; David Schaffer; David Kirn; Peter Francis
Journal:  Int Ophthalmol Clin       Date:  2021-07-01

Review 7.  Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.

Authors:  Kleopatra Rapti; Dirk Grimm
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 8.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

Review 9.  AAV Vectors Vaccines Against Infectious Diseases.

Authors:  Karen Nieto; Anna Salvetti
Journal:  Front Immunol       Date:  2014-01-21       Impact factor: 7.561

Review 10.  Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.

Authors:  Allen Lin; Alejandro B Balazs
Journal:  Retrovirology       Date:  2018-10-01       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.